Loading…
Loading…
EQUITY / NASDAQ · XNCM
Marker Therapeutics, Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.05 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 1.05 USD · Volume 100,299
251 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | Prior year | Change |
|---|---|---|---|
| Operating profit | -2,620,366 USD | — | — |
| Net income | -1,826,229 USD | — | — |
| Cash and cash equivalents | 11,331,023 USD | — | — |
| Total liabilities | 2,420,021 USD | — | — |
| Total equity | 12,165,464 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 203/31/2026 – 03/31/2026ConsolidatedUnits · USD | 2026 / Quarter 101/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 11,331,023 USD | — | — | 14,915,519 USD | 16,068,048 USD | 16,068,048 USD | 17,589,978 USD | — |
| Net incomeIncome statement | -1,826,229 USD | -5,005,507 USD | — | -3,179,278 USD | — | -12,163,620 USD | -1,998,662 USD | -10,460,410 USD |
| Operating profitIncome statement | -2,620,366 USD | -6,692,900 USD | — | -4,072,535 USD | — | -12,890,426 USD | -2,136,726 USD | -11,006,432 USD |
| Total assetsBalance sheet | 14,585,485 USD | — | — | 17,434,008 USD | 19,070,997 USD | 19,070,997 USD | 21,734,830 USD | — |
| Total equityBalance sheet | 12,165,464 USD | — | 13,795,958 USD | 13,795,958 USD | 16,796,814 USD | 16,796,814 USD | 18,388,893 USD | — |
| Total liabilitiesBalance sheet | 2,420,021 USD | — | — | 3,638,050 USD | 2,274,183 USD | 2,274,183 USD | 3,345,937 USD | — |
| Operating cash flowCash flow statement | — | -5,120,515 USD | — | -1,404,192 USD | — | -12,014,081 USD | — | -10,113,975 USD |
| Financing cash flowCash flow statement | — | — | — | — | — | 9,864,488 USD | — | 9,864,488 USD |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 05/15/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 03/18/2026 | Open report ↗ Published: 11/13/2025 | Open report ↗ Published: 11/13/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.